le 135 Search Results


le135  (Tocris)
99
Tocris le135
Le135, supplied by Tocris, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/le135/product/Tocris
Average 99 stars, based on 1 article reviews
le135 - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
rarb antagonist le135  (Tocris)
92
Tocris rarb antagonist le135
Rarb Antagonist Le135, supplied by Tocris, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rarb antagonist le135/product/Tocris
Average 92 stars, based on 1 article reviews
rarb antagonist le135 - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
le135  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology le135
Figure 3. Cellular responses to ATRA in normal and p14ARF-depleted melanocytes. A, BrdUrd incorporation in primary human melanocytes grown for 48 hours in the presence or absence of ATRA (10 mmol/L) and in the presence or absence of <t>LE135</t> (1 mmol/L). B, FACS analysis showing representative cell-cycle profiles of normal human melanocytes cultured for 10 days in the presence or absence of ATRA (10 mmol/L). C, ATRA-induced senescence in two cultures of normal human melanocytes (WT-1 and -2) and two independent pools of melanocytes expressing shRNAs against CDKN2A sequences (HEM-1 and -2). Cells were treated with ATRA (10 mmol/L) for 2 weeks, and the number of senescent cells was determined by SA-b-Gal positivity. Columns represent percentage of SA-b-Gal–positive cells. D, the same data as in (C), but with the increase in senescence in normal melanocytes set at 100%. Statistical analysis was conducted using a paired t test. , P < 0.05; ns, nonsignificant.
Le135, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/le135/product/Santa Cruz Biotechnology
Average 90 stars, based on 1 article reviews
le135 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
beaumont (le mirage iv, 135)  (Dassault Systemes)
90
Dassault Systemes beaumont (le mirage iv, 135)
Figure 3. Cellular responses to ATRA in normal and p14ARF-depleted melanocytes. A, BrdUrd incorporation in primary human melanocytes grown for 48 hours in the presence or absence of ATRA (10 mmol/L) and in the presence or absence of <t>LE135</t> (1 mmol/L). B, FACS analysis showing representative cell-cycle profiles of normal human melanocytes cultured for 10 days in the presence or absence of ATRA (10 mmol/L). C, ATRA-induced senescence in two cultures of normal human melanocytes (WT-1 and -2) and two independent pools of melanocytes expressing shRNAs against CDKN2A sequences (HEM-1 and -2). Cells were treated with ATRA (10 mmol/L) for 2 weeks, and the number of senescent cells was determined by SA-b-Gal positivity. Columns represent percentage of SA-b-Gal–positive cells. D, the same data as in (C), but with the increase in senescence in normal melanocytes set at 100%. Statistical analysis was conducted using a paired t test. , P < 0.05; ns, nonsignificant.
Beaumont (Le Mirage Iv, 135), supplied by Dassault Systemes, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/beaumont (le mirage iv, 135)/product/Dassault Systemes
Average 90 stars, based on 1 article reviews
beaumont (le mirage iv, 135) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
le 135  (Axon Medchem LLC)
90
Axon Medchem LLC le 135
Figure 3. Cellular responses to ATRA in normal and p14ARF-depleted melanocytes. A, BrdUrd incorporation in primary human melanocytes grown for 48 hours in the presence or absence of ATRA (10 mmol/L) and in the presence or absence of <t>LE135</t> (1 mmol/L). B, FACS analysis showing representative cell-cycle profiles of normal human melanocytes cultured for 10 days in the presence or absence of ATRA (10 mmol/L). C, ATRA-induced senescence in two cultures of normal human melanocytes (WT-1 and -2) and two independent pools of melanocytes expressing shRNAs against CDKN2A sequences (HEM-1 and -2). Cells were treated with ATRA (10 mmol/L) for 2 weeks, and the number of senescent cells was determined by SA-b-Gal positivity. Columns represent percentage of SA-b-Gal–positive cells. D, the same data as in (C), but with the increase in senescence in normal melanocytes set at 100%. Statistical analysis was conducted using a paired t test. , P < 0.05; ns, nonsignificant.
Le 135, supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/le 135/product/Axon Medchem LLC
Average 90 stars, based on 1 article reviews
le 135 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
le 135  (Cayman Chemical)
N/A
LE 135 1 mg
   Buy from Supplier
le 135  (Biosynth Carbosynth)
N/A
   Buy from Supplier
le 135  (Aladdin Scientific Corporation)
N/A
Application：LE 135 has been used for in vitro islet treatment.
   Buy from Supplier
le 135  (BOC Sciences)
N/A
LE 135 is a retinoic acid antagonist which shows moderate selectivity for RARβ over RARα It can inhibit human HL 60 leukemia cell differentiation induced by Am80 with IC50 value of 150 nM
   Buy from Supplier

Image Search Results


Figure 3. Cellular responses to ATRA in normal and p14ARF-depleted melanocytes. A, BrdUrd incorporation in primary human melanocytes grown for 48 hours in the presence or absence of ATRA (10 mmol/L) and in the presence or absence of LE135 (1 mmol/L). B, FACS analysis showing representative cell-cycle profiles of normal human melanocytes cultured for 10 days in the presence or absence of ATRA (10 mmol/L). C, ATRA-induced senescence in two cultures of normal human melanocytes (WT-1 and -2) and two independent pools of melanocytes expressing shRNAs against CDKN2A sequences (HEM-1 and -2). Cells were treated with ATRA (10 mmol/L) for 2 weeks, and the number of senescent cells was determined by SA-b-Gal positivity. Columns represent percentage of SA-b-Gal–positive cells. D, the same data as in (C), but with the increase in senescence in normal melanocytes set at 100%. Statistical analysis was conducted using a paired t test. , P < 0.05; ns, nonsignificant.

Journal: Molecular Cancer Research

Article Title: Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identifies a Link Between p14ARF and RARβ Signaling

doi: 10.1158/1541-7786.mcr-13-0006

Figure Lengend Snippet: Figure 3. Cellular responses to ATRA in normal and p14ARF-depleted melanocytes. A, BrdUrd incorporation in primary human melanocytes grown for 48 hours in the presence or absence of ATRA (10 mmol/L) and in the presence or absence of LE135 (1 mmol/L). B, FACS analysis showing representative cell-cycle profiles of normal human melanocytes cultured for 10 days in the presence or absence of ATRA (10 mmol/L). C, ATRA-induced senescence in two cultures of normal human melanocytes (WT-1 and -2) and two independent pools of melanocytes expressing shRNAs against CDKN2A sequences (HEM-1 and -2). Cells were treated with ATRA (10 mmol/L) for 2 weeks, and the number of senescent cells was determined by SA-b-Gal positivity. Columns represent percentage of SA-b-Gal–positive cells. D, the same data as in (C), but with the increase in senescence in normal melanocytes set at 100%. Statistical analysis was conducted using a paired t test. , P < 0.05; ns, nonsignificant.

Article Snippet: LE135 was purchased from Santa Cruz Biotechnology.

Techniques: Cell Culture, Expressing